Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

Next Previous
X
Search
Trial Profile

A Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PRGN-3007 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Advanced breast cancer; B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Haematological malignancies; Mantle-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 08 Jan 2024 According to a Precigen media release, preliminary Phase 1 dose escalation data presentation is anticipated by the end of 2024.
    • 09 Aug 2023 According to a Precigen media release, the Phase 1 dose escalation part of this study is ongoing.
    • 29 Mar 2023 According to a Precigen media release, first patient has been dosed in a CLL patient.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top